10552843

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1626GMS

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page for STN Seminar Schedule - N. America
NEWS 2	JAN 02	STN pricing information for 2008 now available
NEWS 3	JAN 16	CAS patent coverage enhanced to include exemplified prophetic substances
NEWS 4	JAN 28	USPATFULL, USPAT2, and USPATOLD enhanced with new custom IPC display formats
NEWS 5	JAN 28	MARPAT searching enhanced
NEWS 6	JAN 28	USGENE now provides USPTO sequence data within 3 days of publication
NEWS 7	JAN 28	TOXCENTER enhanced with reloaded MEDLINE segment
NEWS 8	JAN 28	MEDLINE and LMEDLINE reloaded with enhancements
NEWS 9	FEB 08	STN Express, Version 8.3, now available
NEWS 10	FEB 20	PCI now available as a replacement to DPCI
NEWS 11	FEB 25	IFIREF reloaded with enhancements
NEWS 12	FEB 25	IMSPRODUCT reloaded with enhancements
NEWS 13	FEB 29	WPINDEX/WPIDS/WPIX enhanced with ECLA and current U.S. National Patent Classification
NEWS 14	MAR 31	IFICDB, IFIPAT, and IFIUDB enhanced with new custom IPC display formats
NEWS 15	MAR 31	CAS REGISTRY enhanced with additional experimental spectra
NEWS 16	MAR 31	CA/CAplus and CASREACT patent number format for U.S. applications updated
NEWS 17	MAR 31	LPCI now available as a replacement to LDPCI
NEWS 18	MAR 31	EMBASE, EMBAL, and LEMBASE reloaded with enhancements
NEWS 19	APR 04	STN AnaVist, Version 1, to be discontinued
NEWS 20	APR 15	WPIDS, WPINDEX, and WPIX enhanced with new predefined hit display formats
NEWS 21	APR 28	EMBASE Controlled Term thesaurus enhanced
NEWS 22	APR 28	IMSRESEARCH reloaded with enhancements
NEWS 23	MAY 30	INPAFAMDB now available on STN for patent family searching
NEWS 24	MAY 30	DGENE, PCTGEN, and USGENE enhanced with new homology sequence search option
NEWS 25	JUN 06	EPFULL enhanced with 260,000 English abstracts
NEWS 26	JUN 06	KOREAPAT updated with 41,000 documents
NEWS 27	JUN 13	USPATFULL and USPAT2 updated with 11-character patent numbers for U.S. applications
NEWS 28	JUN 19	CAS REGISTRY includes selected substances from web-based collections
NEWS 29	JUN 25	CA/CAplus and USPAT databases updated with IPC

reclassification data
NEWS 30 JUN 30 AEROSPACE enhanced with more than 1 million U.S. patent records
NEWS 31 JUN 30 EMBASE, EMBAL, and LEMBASE updated with additional options to display authors and affiliated organizations
NEWS 32 JUN 30 STN on the Web enhanced with new STN AnaVist Assistant and BLAST plug-in
NEWS 33 JUN 30 STN AnaVist enhanced with database content from EPFULL

NEWS EXPRESS JUNE 27 08 CURRENT WINDOWS VERSION IS V8.3,
AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items
NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 08:39:55 ON 16 JUL 2008

=> FIL HCAPLUS
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION
FULL ESTIMATED COST 0.21 0.21

FILE 'HCAPLUS' ENTERED AT 08:40:06 ON 16 JUL 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 16 Jul 2008 VOL 149 ISS 3
FILE LAST UPDATED: 15 Jul 2008 (20080715/ED)

HCAplus now includes complete International Patent Classification (IPC) reclassification data for the second quarter of 2008.

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

```
=> s carvedilol
          1943 CARVEDILOL
             1 CARVEDILOLS
L1        1943 CARVEDILOL
                (CARVEDILOL OR CARVEDILOLS)

=> s l1 and process for the preparation
       2646810 PROCESS
       1809331 PROCESSES
       3948295 PROCESS
                (PROCESS OR PROCESSES)
       1620414 PREPARATION
         83372 PREPARATIONS
       1699244 PREPARATION
                (PREPARATION OR PREPARATIONS)
       2925536 PREPN
        214166 PREPNS
       3086606 PREPN
                (PREPN OR PREPNS)
       3973999 PREPARATION
                (PREPARATION OR PREPN)
         66630 PROCESS FOR THE PREPARATION
                (PROCESS(2W)PREPARATION)
L2          30 L1 AND PROCESS FOR THE PREPARATION

=> s l2 and organic acid
        414983 ORGANIC
          4035 ORGANICS
        417584 ORGANIC
                (ORGANIC OR ORGANICS)
       1084845 ORG
         16835 ORGS
       1091017 ORG
                (ORG OR ORGS)
       1207500 ORGANIC
                (ORGANIC OR ORG)
       4626919 ACID
       1640422 ACIDS
       5141676 ACID
                (ACID OR ACIDS)
         63026 ORGANIC ACID
                (ORGANIC(W)ACID)
L3           0 L2 AND ORGANIC ACID

=> s l2 and organic solvent
        414983 ORGANIC
          4035 ORGANICS
        417584 ORGANIC
                (ORGANIC OR ORGANICS)
       1084845 ORG
         16835 ORGS
       1091017 ORG
```

```
                (ORG OR ORGS)
      1207500 ORGANIC
                (ORGANIC OR ORG)
       745892 SOLVENT
       358054 SOLVENTS
       930966 SOLVENT
                (SOLVENT OR SOLVENTS)
       158616 ORGANIC SOLVENT
                (ORGANIC(W)SOLVENT)
L4           4 L2 AND ORGANIC SOLVENT

=> s l2 and salts
       649684 SALTS
L5           9 L2 AND SALTS

=> s l2 and oxalic acid
        52412 OXALIC
            1 OXALICS
        52413 OXALIC
                (OXALIC OR OXALICS)
      4626919 ACID
      1640422 ACIDS
      5141676 ACID
                (ACID OR ACIDS)
        48958 OXALIC ACID
                (OXALIC(W)ACID)
L6           3 L2 AND OXALIC ACID

=> s l2 and salicylic acid
        44003 SALICYLIC
            2 SALICYLICS
        44004 SALICYLIC
                (SALICYLIC OR SALICYLICS)
      4626919 ACID
      1640422 ACIDS
      5141676 ACID
                (ACID OR ACIDS)
        42236 SALICYLIC ACID
                (SALICYLIC(W)ACID)
L7           2 L2 AND SALICYLIC ACID

=> s l2 and sslts of carvedilol
            0 SSLTS
         1943 CARVEDILOL
            1 CARVEDILOLS
         1943 CARVEDILOL
                (CARVEDILOL OR CARVEDILOLS)
            0 SSLTS OF CARVEDILOL
                (SSLTS(1W)CARVEDILOL)
L8           0 L2 AND SSLTS OF CARVEDILOL

=> s l2 and salts of carvedilol
       649684 SALTS
         1943 CARVEDILOL
            1 CARVEDILOLS
         1943 CARVEDILOL
                (CARVEDILOL OR CARVEDILOLS)
```

```
             4 SALTS OF CARVEDILOL
               (SALTS(1W)CARVEDILOL)
L9           1 L2 AND SALTS OF CARVEDILOL

=> s l2 and crystalline
         86191 CRYSTALLINE
           270 CRYSTALLINES
         86439 CRYSTALLINE
               (CRYSTALLINE OR CRYSTALLINES)
        374190 CRYST
          1802 CRYSTS
        375459 CRYST
               (CRYST OR CRYSTS)
        405880 CRYSTALLINE
               (CRYSTALLINE OR CRYST)
L10          6 L2 AND CRYSTALLINE

=> s l10 and form II
       1735442 FORM
        656949 FORMS
       2234838 FORM
               (FORM OR FORMS)
       2230368 II
          1072 IIS
       2230991 II
               (II OR IIS)
          4787 FORM II
               (FORM(W)II)
L11          2 L10 AND FORM II

=> d his

     (FILE 'HOME' ENTERED AT 08:39:55 ON 16 JUL 2008)

     FILE 'HCAPLUS' ENTERED AT 08:40:06 ON 16 JUL 2008
L1          1943 S CARVEDILOL
L2            30 S L1 AND PROCESS FOR THE PREPARATION
L3             0 S L2 AND ORGANIC ACID
L4             4 S L2 AND ORGANIC SOLVENT
L5             9 S L2 AND SALTS
L6             3 S L2 AND OXALIC ACID
L7             2 S L2 AND SALICYLIC ACID
L8             0 S L2 AND SSLTS OF CARVEDILOL
L9             1 S L2 AND SALTS OF CARVEDILOL
L10            6 S L2 AND CRYSTALLINE
L11            2 S L10 AND FORM II

=> s l2 and py<=2003
      23986215 PY<=2003
L12          6 L2 AND PY<=2003

=> d l4 ibib abs hitstr tot

L4   ANSWER 1 OF 4  HCAPLUS  COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER:         2008:411850  HCAPLUS
DOCUMENT NUMBER:          148:403079
TITLE:                    Process for preparation of
```

carvedilol from 4-hydroxycarbazole, epichlorohydrin, and 2-(2-methoxyphenoxy)ethylamine.
INVENTOR(S): Suri, Sanjay; Kashyap, Tapan
PATENT ASSIGNEE(S): Morepen Laboratories Limited, India
SOURCE: PCT Int. Appl., 21pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008038301	A1	20080403	WO 2007-IN389	20070905
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
IN 2006DE01711	A	20080404	IN 2006-DE1711	20060926
PRIORITY APPLN. INFO.:			IN 2006-DE1711 A	20060926

OTHER SOURCE(S): CASREACT 148:403079
AB Carvedilol (I) was prepared by reaction of 4-hydroxycarbazole with epichlorohydrin in an organic solvent in the presence of base, isolation of the intermediate 4-(2,3-epoxypropoxy)carbazole as a solid cake and reaction of this with 2-(2-methoxyphenoxy)ethylamine in an organic solvent. The crude I is converted to pure product either through solvent crystallization (without salt formation) or through salt formation followed by salt cleavage and solvent crystallization
REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 4 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2005:1288806 HCAPLUS
DOCUMENT NUMBER: 144:22811
TITLE: A novel process for the preparation of 1-(9H-carbazol-4-yloxy)-3-[[2-(-methoxyphenoxy)-ethyl] amino]-propan-2-ol (carvedilol)
INVENTOR(S): Tarur, Venkatasubramanian Radhakrishnan; Sathe, Dhananjay Govind; Kulkarni, Swapnil Jayant
PATENT ASSIGNEE(S): USV Limited, India
SOURCE: PCT Int. Appl., 14 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

WO 2005115981 A2 20051208 WO 2005-IN139 20050503
WO 2005115981 A3 20060119
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
IN 2004MU00479 A 20060616 IN 2004-MU479 20040422
US 20070191456 A1 20070816 US 2006-568732 20061227
PRIORITY APPLN. INFO.: IN 2004-MU479 A 20040422
WO 2005-IN139 W 20050503

OTHER SOURCE(S): CASREACT 144:22811
GI



I

AB This invention disclosed a novel process for preparation of carvedilol (I) in high purity by using eco friendly solvents. The process comprised reacting 4-hydroxycarbazole with epichlorhydrin in presence of an organic solvent and a base at temps. between 10° and 30°, and then reacting the resultant 4-(2,3-epoxypropoxy)carbazole with a salt of 2-(2-methoxyphenoxy)ethylamine, preferably the hydrochloride salt, in presence of a base and a hydroxylic solvent at temps. between 30° and 90°.

L4 ANSWER 3 OF 4 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2004:1154673 HCAPLUS
DOCUMENT NUMBER: 142:93675
TITLE: A process for preparation of 1-[9H-carbazol-4-yloxy]-3-[[2-(2-methoxyphenoxy)ethyl]amino]propan-2-ol
INVENTOR(S): Chhabada, Vijay Chhangamal; Rehani, Rajeev Budhdev; Thennati, Rajamannar
PATENT ASSIGNEE(S): Sun Pharmaceutical Industries Limited, India
SOURCE: PCT Int. Appl., 27 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004113296	A1	20041229	WO 2004-IN52	20040304
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
IN 2003MU00647	A	20050211	IN 2003-MU647	20030620
US 20060270858	A1	20061130	US 2005-553957	20051019
PRIORITY APPLN. INFO.:			IN 2003-MU647 A	20030620
			IN 2003-MU721 A	20030717
			WO 2004-IN52 W	20040304

OTHER SOURCE(S): CASREACT 142:93675; MARPAT 142:93675
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The present invention provides a process for preparation of 1-[9H-carbazol-4-yloxy]-3-[[2-(2-methoxyphenoxy)ethyl]amino]-propan-2-ol (I) in racemic form or in the form of optically active R or S enantiomer or its pharmaceutically acceptable salt, comprising, reacting 4-(oxiranylmethoxy)-9H-carbazole (II) or the R or S enantiomer thereof with a compound of formula (III) (wherein R1 = benzyl or substituted benzyl), in an aprotic organic solvent in presence of a catalyst to obtain a compound of formula (IV) (wherein R1 is as defined above), or the R or S enantiomer thereof. The resultant compound IV is subjected to debenzylation reaction by catalytic hydrogenation to obtain the compound I, if desired converting the resultant compound I to a pharmaceutically acceptable salt thereof. Thus, to 400 mL EtOAc, 70 g (0.27 mol) anhydrous N-[2-[2-(methoxy)phenoxy]ethyl]benzylamine, 10.25 g (0.075 mol) anhydrous ZnCl2, and 50 g (0.21 mol) 4-(oxiranylmethoxy)-9H-carbazole were added and the reaction mixture was heated to 70-75° for 3 h (TLC control for checking conversion to N-benzylcarvedilol), cooled to ambient temperature, and quenched into 100 mL 12-15% aqueous NH3. The aqueous layer was separated, and the product enriched organic layer was washed with water till neutral Ph, treated with charcoal, and filtered. To this solution of N-benzyl carvedilol in EtOAc, 7 g wet 5% Pd/C catalyst (50% moisture content) was added and the reaction mixture was hydrogenated at 3.5-4.5 Kg/cm2 at temperature 60-70° for a period of about 10 h and filtered. The filtrate was concentrated to remove EtOAc. To the resultant syrupy mass n-butanol (100 mL) was added and the solution was stirred for .apprx.10 h. The crystals were separated by filtration, washed successively with n-butanol (50 mL) and toluene (50 mL) to obtain carvedilol (47 g) which was recrystd. from 3 vols. EtOAc to obtain carvedilol

(42 g).
REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 4 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2004:927171 HCAPLUS
DOCUMENT NUMBER: 141:395415
TITLE: Process for the preparation of crystalline carvedilol form-II
INVENTOR(S): Ramanjaneyulu, Gorantla Seeta; Kumar, Indukuri Venkata Sunil; Rao, Ketavarapu Narasimha; Kishore, Jammula Vera Venkata Krishna
PATENT ASSIGNEE(S): Matrix Laboratories Ltd., India
SOURCE: PCT Int. Appl., 18 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004094378	A1	20041104	WO 2004-IN104	20040416
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
IN 2003MA00328	A	20070518	IN 2003-MA328	20030421
EP 1615888	A1	20060118	EP 2004-727971	20040416
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
US 20070055069	A1	20070308	US 2005-552843	20051012
PRIORITY APPLN. INFO.:			IN 2003-MA328 A	20030421
			WO 2004-IN104 W	20040416

OTHER SOURCE(S): CASREACT 141:395415
AB The present invention provides a cost-effective, industrially feasible process for the manufacture of crystalline carvedilol form-II using novel carvedilol salts comprising a step of reacting 4-(2,3-epoxypropoxy)carbazole with 2-(2-methoxyphenoxy)ethylamine followed by acidification with mineral acid in presence of an organic solvent to yield acid addition salts, (e.g. carvedilol oxalate), treatment of the said salts with base(s) in presence of organic solvent(s), water, and isolation from the organic solvent(s) followed by crystallization from Et acetate.
REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d l5 ibib abs hitstr tot

L5 ANSWER 1 OF 9 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2008:824932 HCAPLUS
TITLE: Carvedilol compositions
INVENTOR(S): Patil, Atul Vishvanath; Vishwanathan, Narayanan Badri; Bhushan, Indu; Reddy, Gade Srinivas; Reddy, Mallepalli Srinivas; Reddy, Kasaraddy Padmaja
PATENT ASSIGNEE(S): Dr. Reddy's Laboratories Limited, India; Dr. Reddy's Laboratories, Inc.
SOURCE: PCT Int. Appl., 64pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008083130	A2	20080710	WO 2007-US88774	20071224
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

PRIORITY APPLN. INFO.: IN 2006-CH2424 A 20061226
US 2007-894712P P 20070314
IN 2007-CH1279 A 20070620

AB Amorphous carvedilol or its pharmaceutically acceptable salts, their processes of preparation and pharmaceutical compns. An aspect of the invention relates to amorphous carvedilol phosphate, processes of preparation, and its pharmaceutical compns.

L5 ANSWER 2 OF 9 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2008:639197 HCAPLUS
DOCUMENT NUMBER: 148:593035
TITLE: Programmable drug delivery technology
INVENTOR(S): Singh, Amarjit; Singh, Sarabjit; Puthli, Shivanand; Tandale, Rajendra
PATENT ASSIGNEE(S): Panacea Biotec Limited, India
SOURCE: PCT Int. Appl., 50pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008062440	A2	20080529	WO 2007-IN392	20070903
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA,				

CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: IN 2006-MU1411 A 20060904

AB The present invention is concerned with a system for spatially and temporally programmable delivery of an active agent. When administered orally, the system can be retained in the gastric region for a prolonged period of time. It comprises a core, one or more layers coated over the core and a preformed hollow space. The invention also concerns with a process for preparation of the system and a method for treating/preventing diseases, by administering to a subject in need thereof, the system of the invention.

L5 ANSWER 3 OF 9 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2007:963587 HCAPLUS

DOCUMENT NUMBER: 147:308201

TITLE: Novel buccoadhesive compositions comprising a polymer and a sugar and process of preparation thereof

INVENTOR(S): Jain, Rajesh; Jindal, Kour Chand; Devarajan, Sampath Kumar

PATENT ASSIGNEE(S): Panacea Biotec Ltd., India

SOURCE: PCT Int. Appl., 45pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007096906	A2	20070830	WO 2007-IN74	20070223
WO 2007096906	A3	20071018		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA

PRIORITY APPLN. INFO.: IN 2006-DE512 A 20060227

AB Novel buccoadhesive compns. comprising at least one bioactive agent(s), at least one bioadhesive polymer(s), at least one water soluble sugar component(s) and at least one binder(s), optionally with other excipients

are provided, wherein the said composition has improved cohesiveness, enhanced intactness and improved adhesion at the desired site of the mucosa for substantially longer duration and releases the bioactive agent(s) in a sustained manner in the oral cavity for extended time period. The composition releases the bioactive agent(s) in the oral cavity such that the bioactive agent is absorbed through the mucosal tissues of the oral cavity thereby bypassing the hepatic metabolism and resulting in increased bioavailability. The bioactive agent(s) is a pharmaceutically active agent(s) or a nutritional supplement(s) or a food product(s), or combinations thereof. Also provided is a process of preparation of such novel compns. comprising steps of (i) mixing the bioactive agent(s) or bioactive agent(s) complexed with cyclodextrin with filler(s); buccoadhesive polymer(s), binder(s), sweetener(s), sugar, color and flavor, optionally with other excipients, (ii) mixing the contents in step (i) with one part of lubricant(s) and roller compacting the blend to obtain compacts, (iii) crushing the compacts/slugs and passing the compacts through suitable sieve to obtain granules, (iv) mixing the granules with the remaining part of lubricant(s) optionally with other excipients, and (v) optionally compressing the blend of step (iv) into a suitable compressed dosage form. Thus, a tablet was prepared containing ondansetron/hydroxypropyl β-cyclodextrin complex 24.36 mg (equivalent to 8 mg of ondansetron base), sodium CM-cellulose (Blanose 7H4XF) 15.00 mg, Plasdone S 630 5.00 mg, maltodextrin 10.00 mg, sucrose 13.16 mg, aspartame 1.00 mg, sodium stearyl fumarate 0.70 mg, Lake of erythrosine 0.07 mg, and strawberry flavor 0.70 mg.

L5 ANSWER 4 OF 9 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2007:770875 HCAPLUS
DOCUMENT NUMBER: 148:545974
TITLE: A novel cost effective process for production of carvedilol phosphate
INVENTOR(S): Shankar, Sanganbhatla; Pandurang, Suryavanshi Jitendra; Sayyed, Zahid Alam
PATENT ASSIGNEE(S): Wanbury Limited, India
SOURCE: Indian Pat. Appl., 13pp.
CODEN: INXXBQ
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
IN 2007MU00929	A	20070706	IN 2007-MU929	20070517
PRIORITY APPLN. INFO.:			IN 2007-MU929	20070517

AB A novel cost effective process for the synthesis of phosphate salts of 1-(9H-carbazol-4yloxy)-3-[[2-(2-methoxyphenoxy)ethyl] amino]-propan-2-ol,(carvedilol phosphate) of formula (II) with high yields and purity is disclosed. More particularly, the invention discloses a process of preparation of crystalline phosphate salts of carvedilol using various phosphonation reagents such as phosphorous pentoxide, polyphosphoric acid, Dipotassium hydrogen phosphate, Ammonium Dihydrogen ortho phosphate, and Sodium Dihydrogen ortho phosphate in solvents selected from Acetonitrile, acetone and THF. The solvents used to prepare solvates of carvedilol dihydrogen phosphate are methanol, ethanol and iso-Pr alc.

L5 ANSWER 5 OF 9 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2004:927171 HCAPLUS
DOCUMENT NUMBER: 141:395415
TITLE: Process for the preparation of crystalline carvedilol form-II
INVENTOR(S): Ramanjaneyulu, Gorantla Seeta; Kumar, Indukuri Venkata Sunil; Rao, Ketavarapu Narasimha; Kishore, Jammula Vera Venkata Krishna
PATENT ASSIGNEE(S): Matrix Laboratories Ltd., India
SOURCE: PCT Int. Appl., 18 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004094378	A1	20041104	WO 2004-IN104	20040416
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
IN 2003MA00328	A	20070518	IN 2003-MA328	20030421
EP 1615888	A1	20060118	EP 2004-727971	20040416
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
US 20070055069	A1	20070308	US 2005-552843	20051012

PRIORITY APPLN. INFO.: IN 2003-MA328 A 20030421
WO 2004-IN104 W 20040416
OTHER SOURCE(S): CASREACT 141:395415
AB The present invention provides a cost-effective, industrially feasible process for the manufacture of crystalline carvedilol form-II using novel carvedilol salts comprising a step of reacting 4-(2,3-epoxypropoxy)carbazole with 2-(2-methoxyphenoxy)ethylamine followed by acidification with mineral acid in presence of an organic solvent to yield acid addition salts, (e.g. carvedilol oxalate), treatment of the said salts with base(s) in presence of organic solvent(s), water, and isolation from the organic solvent(s) followed by crystallization from Et acetate.
REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 6 OF 9 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2004:412919 HCAPLUS
DOCUMENT NUMBER: 140:406735
TITLE: Process for the preparation of carvedilol from 4-(oxirane-2-ylmethoxy)-9H-carbazole and 2-(2-methoxyphenoxy)ethylamine

salts
INVENTOR(S): Hercek, Richard; Skoda, Alojz; Proksa, Bohumil
PATENT ASSIGNEE(S): Zentiva, A.S., Slovakia
SOURCE: PCT Int. Appl., 13 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004041783	A1	20040521	WO 2003-SK20	20031104
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
SK 285547	B6	20070301	SK 2002-1595	20021108
AU 2003301861	A1	20040607	AU 2003-301861	20031104
EP 1558575	A1	20050803	EP 2003-810732	20031104
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
US 20060167077	A1	20060727	US 2005-533809	20050505
PRIORITY APPLN. INFO.:			SK 2002-1595 A	20021108
			WO 2003-SK20 W	20031104

OTHER SOURCE(S): CASREACT 140:406735
AB Carvedilol is prepared in high yield and selectivity by the reaction of 4-(oxirane-2-ylmethoxy)-9H-carbazole with acid-addition salts of 2-(2-methoxyphenoxy)ethylamine [e.g., 2-(2-methoxyphenoxy)ethylamine hydrochloride] in the presence of a base (e.g., potassium carbonate) in an C2-5 alc. solvent (e.g., isopropanol) at an elevated temperature (e.g., 83°).

L5 ANSWER 7 OF 9 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2003:282536 HCAPLUS
DOCUMENT NUMBER: 138:292802
TITLE: Pseudopolymorphic forms of carvedilol
INVENTOR(S): Bubendorf, Andre Gerard; Gabel, Rolf-dieter; Henning, Michael; Krimmer, Siegfried; Neugebauer, Guenter; Preis, Walter; Wirl, Alexander
PATENT ASSIGNEE(S): F. Hoffmann-La Roche Ag, Switz.
SOURCE: PCT Int. Appl., 35 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003029214	A1	20030410	WO 2002-EP10451	20020918

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

CA 2460486	A1	20030410	CA 2002-2460486		20020918
AU 2002338726	B9	20030414	AU 2002-338726		20020918
AU 2002338726	A1	20030414			
AU 2002338726	B2	20070315			
EP 1432681	A1	20040630	EP 2002-777139		20020918
EP 1432681	B1	20070808			

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK

BR 2002012927	A	20041013	BR 2002-12927		20020918
CN 1558900	A	20041229	CN 2002-818741		20020918
JP 2005507899	T	20050324	JP 2003-532464		20020918
AT 369339	T	20070815	AT 2002-777139		20020918
RU 2308449	C2	20071020	RU 2004-113209		20020918
ES 2291503	T3	20080301	ES 2002-777139		20020918
US 20030119893	A1	20030626	US 2002-255290		20020926
MX 2004PA02826	A	20040702	MX 2004-PA2826		20040325
KR 752549	B1	20070830	KR 2004-704578		20040327
US 20040198812	A1	20041007	US 2004-827859		20040420
US 20060148878	A1	20060706	US 2006-325754		20060105
PRIORITY APPLN. INFO.:			EP 2001-123422	A	20010928
			WO 2002-EP10451	W	20020918
			US 2002-255290	B1	20020926
			US 2004-827859	B1	20040420

AB The present invention is related to pseudopolymorphic forms of 1-(4-carbazolyloxy)-3[2-(2-methoxyphenoxy)ethylamino]-2-propanol (carvedilol) or its optically active forms or pharmaceutically acceptable salts, processes for their prepn ., and pharmaceutical comprns. containing them for the treatment or prophylaxis of cardiac diseases.

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 8 OF 9 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1999:96212 HCAPLUS
DOCUMENT NUMBER: 130:158418
TITLE: Thermodynamically stable modification of 1-(4-carbazolyloxy)-3-[2-(2-methoxyphenoxy)ethylamino]-2-propanol, process for its preparation and pharmaceutical compositions containing it
INVENTOR(S): Reinholz, Erhard; Beyer, Peter
PATENT ASSIGNEE(S): Boehringer Mannheim G.m.b.H., Germany
SOURCE: PCT Int. Appl., 20 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9905105	A1	19990204	WO 1998-EP4475	19980718
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 893440	A1	19990127	EP 1997-112491	19970722
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
CA 2296637	A1	19990204	CA 1998-2296637	19980718
CA 2296637	C	20051115		
AU 9886319	A	19990216	AU 1998-86319	19980718
AU 740453	B2	20011101		
EP 1000027	A1	20000517	EP 1998-937576	19980718
EP 1000027	B1	20030402		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
BR 9810776	A	20000919	BR 1998-10776	19980718
HU 2000003198	A2	20010328	HU 2000-3198	19980718
HU 2000003198	A3	20021028		
JP 2001510824	T	20010807	JP 2000-504104	19980718
NZ 502136	A	20020531	NZ 1998-502136	19980718
AT 236123	T	20030415	AT 1998-937576	19980718
RU 2202542	C2	20030420	RU 2000-103033	19980718
IL 133677	A	20040601	IL 1998-133677	19980718
PL 191602	B1	20060630	PL 1998-338432	19980718
MX 200000507	A	20001109	MX 2000-507	20000113
NO 2000000301	A	20000121	NO 2000-301	20000121
NO 313588	B1	20021028		
HK 1029339	A1	20040213	HK 2001-100012	20010102
US 20030036559	A1	20030220	US 2002-166188	20020610
US 6730326	B2	20040504		

PRIORITY APPLN. INFO.:	EP 1997-112491	A	19970722
	WO 1998-EP4475	W	19980718
	US 2000-463346	B1	20000121

AB The present invention relates to a new thermodynamically stable modification of Carvedilol, pharmacol. acceptable salts , or optically active forms thereof, processes for the preparation, and pharmaceutical compns. containing it. Crude carvedilol is heated with MeOH and CXA-coal to give forms I and II and these are recrystd. in isopropanol to give pure form I.

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 9 OF 9 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1999:90419 HCAPLUS
DOCUMENT NUMBER: 130:144175
TITLE: Thermodynamically stable modification of carvedilol, process for its preparation and pharmaceutical compositions

containing it
INVENTOR(S): Beyer, Peter; Reinholz, Erhard
PATENT ASSIGNEE(S): Boehringer Mannheim GmbH, Germany
SOURCE: Eur. Pat. Appl., 11 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 893440	A1	19990127	EP 1997-112491	19970722
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
IN 1998MA01596	A	20050304	IN 1998-MA1596	19980717
CA 2296637	A1	19990204	CA 1998-2296637	19980718
CA 2296637	C	20051115		
WO 9905105	A1	19990204	WO 1998-EP4475	19980718
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 9886319	A	19990216	AU 1998-86319	19980718
AU 740453	B2	20011101		
EP 1000027	A1	20000517	EP 1998-937576	19980718
EP 1000027	B1	20030402		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
TR 200000148	T2	20000721	TR 2000-148	19980718
BR 9810776	A	20000919	BR 1998-10776	19980718
HU 2000003198	A2	20010328	HU 2000-3198	19980718
HU 2000003198	A3	20021028		
JP 2001510824	T	20010807	JP 2000-504104	19980718
NZ 502136	A	20020531	NZ 1998-502136	19980718
TW 505631	B	20021011	TW 1998-87111738	19980718
AT 236123	T	20030415	AT 1998-937576	19980718
RU 2202542	C2	20030420	RU 2000-103033	19980718
PT 1000027	T	20030731	PT 1998-937576	19980718
CN 1125047	B	20031022	CN 1998-807436	19980718
ES 2195366	T3	20031201	ES 1998-937576	19980718
IL 133677	A	20040601	IL 1998-133677	19980718
PL 191602	B1	20060630	PL 1998-338432	19980718
CZ 296947	B6	20060816	CZ 2000-221	19980718
ZA 9806475	A	20000121	ZA 1998-6475	19980721
MX 200000507	A	20001109	MX 2000-507	20000113
NO 2000000301	A	20000121	NO 2000-301	20000121
NO 313588	B1	20021028		
HK 1029339	A1	20040213	HK 2001-100012	20010102
US 20030036559	A1	20030220	US 2002-166188	20020610
US 6730326	B2	20040504		

PRIORITY APPLN. INFO.:			
	EP 1997-112491	A	19970722
	WO 1998-EP4475	W	19980718

US 2000-463346 B1 20000121

AB A new thermodynamically stable modification of 1-(4-carbazolyloxy)-3-[2-(2-methoxyphenoxy)ethylamino]-2-propanol (carvedilol), pharmacol. acceptable salts, or optically active forms thereof, processes for the preparation, and pharmaceutical compns. containing it is disclosed. Thus, 300 g crude carvedilol, 15 g CXA-coal and 2800 methanol was heated for 15 min under reflux, then the hot solution was filtered, washed with 300 mL hot methanol and heated under reflux again. Subsequently the solution was cooled down to 0° and the product was isolated, washed with methanol and dried to obtain 203-255 g of pure form I. Form II can be obtained by addnl. recrystn. process in isopropanol.

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d l6 ibib abs hitstr tot

L6 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2008:411850 HCAPLUS
DOCUMENT NUMBER: 148:403079
TITLE: Process for preparation of carvedilol from 4-hydroxycarbazole, epichlorohydrin, and 2-(2-methoxyphenoxy)ethylamine.
INVENTOR(S): Suri, Sanjay; Kashyap, Tapan
PATENT ASSIGNEE(S): Morepen Laboratories Limited, India
SOURCE: PCT Int. Appl., 21pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008038301	A1	20080403	WO 2007-IN389	20070905
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
IN 2006DE01711	A	20080404	IN 2006-DE1711	20060926
PRIORITY APPLN. INFO.:			IN 2006-DE1711 A	20060926

OTHER SOURCE(S): CASREACT 148:403079

AB Carvedilol (I) was prepared by reaction of 4-hydroxycarbazole with epichlorohydrin in an organic solvent in the presence of base, isolation of the intermediate 4-(2,3-epoxypropoxy)carbazole as a solid cake and reaction of this with 2-(2-methoxyphenoxy)ethylamine in an organic solvent. The crude I is converted to pure product either through solvent crystallization (without salt formation) or through salt formation followed by salt

cleavage and solvent crystallization
REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 2 OF 3 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2004:1154673 HCAPLUS
DOCUMENT NUMBER: 142:93675
TITLE: A process for preparation of 1-[9H-carbazol-4-yloxy]-3-[[2-(2-methoxyphenoxy)ethyl]amino]propan-2-ol
INVENTOR(S): Chhabada, Vijay Chhangamal; Rehani, Rajeev Budhdev; Thennati, Rajamannar
PATENT ASSIGNEE(S): Sun Pharmaceutical Industries Limited, India
SOURCE: PCT Int. Appl., 27 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004113296	A1	20041229	WO 2004-IN52	20040304
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
IN 2003MU00647	A	20050211	IN 2003-MU647	20030620
US 20060270858	A1	20061130	US 2005-553957	20051019
PRIORITY APPLN. INFO.:			IN 2003-MU647 A	20030620
			IN 2003-MU721 A	20030717
			WO 2004-IN52 W	20040304

OTHER SOURCE(S): CASREACT 142:93675; MARPAT 142:93675
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The present invention provides a process for preparation of 1-[9H-carbazol-4-yloxy]-3-[[2-(2-methoxyphenoxy)ethyl]amino]-propan-2-ol (I) in racemic form or in the form of optically active R or S enantiomer or its pharmaceutically acceptable salt, comprising, reacting 4-(oxiranylmethoxy)-9H-carbazole (II) or the R or S enantiomer thereof with a compound of formula (III) (wherein R1 = benzyl or substituted benzyl), in an aprotic organic solvent in presence of a catalyst to obtain a compound of formula (IV) (wherein R1 is as defined above), or the R or S enantiomer thereof. The resultant compound IV is subjected to debenzylation reaction by catalytic hydrogenation to obtain the compound I, if desired

converting the resultant compound I to a pharmaceutically acceptable salt thereof. Thus, to 400 mL EtOAc, 70 g (0.27 mol) anhydrous N-[2-[2-(methoxy)phenoxy]ethyl]benzylamine, 10.25 g (0.075 mol) anhydrous ZnCl2, and 50 g (0.21 mol) 4-(oxiranylmethoxy)-9H-carbazole were added and the reaction mixture was heated to 70-75° for 3 h (TLC control for checking conversion to N-benzylcarvedilol), cooled to ambient temperature, and quenched into 100 mL 12-15% aqueous NH3. The aqueous layer was separated, and the product enriched organic layer was washed with water till neutral Ph, treated with charcoal, and filtered. To this solution of N-benzyl carvedilol in EtOAc, 7 g wet 5% Pd/C catalyst (50% moisture content) was added and the reaction mixture was hydrogenated at 3.5-4.5 Kg/cm2 at temperature 60-70° for a period of about 10 h and filtered. The filtrate was concentrated to remove EtOAc. To the resultant syrupy mass n-butanol (100 mL) was added and the solution was stirred for .apprx.10 h. The crystals were separated by filtration, washed successively with n-butanol (50 mL) and toluene (50 mL) to obtain carvedilol (47 g) which was recrystd. from 3 vols. EtOAc to obtain carvedilol (42 g).

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:927171 HCAPLUS
DOCUMENT NUMBER: 141:395415
TITLE: Process for the preparation of crystalline carvedilol form-II
INVENTOR(S): Ramanjaneyulu, Gorantla Seeta; Kumar, Indukuri Venkata Sunil; Rao, Ketavarapu Narasimha; Kishore, Jammula Vera Venkata Krishna
PATENT ASSIGNEE(S): Matrix Laboratories Ltd., India
SOURCE: PCT Int. Appl., 18 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004094378	A1	20041104	WO 2004-IN104	20040416
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
IN 2003MA00328	A	20070518	IN 2003-MA328	20030421
EP 1615888	A1	20060118	EP 2004-727971	20040416
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
US 20070055069	A1	20070308	US 2005-552843	20051012
PRIORITY APPLN. INFO.:			IN 2003-MA328 A	20030421

WO 2004-IN104 W 20040416

OTHER SOURCE(S): CASREACT 141:395415

AB The present invention provides a cost-effective, industrially feasible process for the manufacture of crystalline carvedilol form-II using novel carvedilol salts comprising a step of reacting 4-(2,3-epoxypropoxy)carbazole with 2-(2-methoxyphenoxy)ethylamine followed by acidification with mineral acid in presence of an organic solvent to yield acid addition salts, (e.g. carvedilol oxalate), treatment of the said salts with base(s) in presence of organic solvent(s), water, and isolation from the organic solvent(s) followed by crystallization from Et acetate.

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d l7 ibib abs hitstr tot

L7 ANSWER 1 OF 2 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2008:411850 HCAPLUS

DOCUMENT NUMBER: 148:403079

TITLE: Process for preparation of carvedilol from 4-hydroxycarbazole, epichlorohydrin, and 2-(2-methoxyphenoxy)ethylamine.

INVENTOR(S): Suri, Sanjay; Kashyap, Tapan

PATENT ASSIGNEE(S): Morepen Laboratories Limited, India

SOURCE: PCT Int. Appl., 21pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008038301	A1	20080403	WO 2007-IN389	20070905
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
IN 2006DE01711	A	20080404	IN 2006-DE1711	20060926
PRIORITY APPLN. INFO.:			IN 2006-DE1711 A	20060926

OTHER SOURCE(S): CASREACT 148:403079

AB Carvedilol (I) was prepared by reaction of 4-hydroxycarbazole with epichlorohydrin in an organic solvent in the presence of base, isolation of the intermediate 4-(2,3-epoxypropoxy)carbazole as a solid cake and reaction of this with 2-(2-methoxyphenoxy)ethylamine in an organic solvent. The crude I is converted to pure product either through solvent crystallization (without salt formation) or through salt formation followed by salt cleavage and solvent crystallization

REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2004:927171 HCAPLUS
DOCUMENT NUMBER: 141:395415
TITLE: Process for the preparation of crystalline carvedilol form-II
INVENTOR(S): Ramanjaneyulu, Gorantla Seeta; Kumar, Indukuri Venkata Sunil; Rao, Ketavarapu Narasimha; Kishore, Jammula Vera Venkata Krishna
PATENT ASSIGNEE(S): Matrix Laboratories Ltd., India
SOURCE: PCT Int. Appl., 18 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004094378	A1	20041104	WO 2004-IN104	20040416
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
IN 2003MA00328	A	20070518	IN 2003-MA328	20030421
EP 1615888	A1	20060118	EP 2004-727971	20040416
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
US 20070055069	A1	20070308	US 2005-552843	20051012
PRIORITY APPLN. INFO.:			IN 2003-MA328 A	20030421
			WO 2004-IN104 W	20040416

OTHER SOURCE(S): CASREACT 141:395415
AB The present invention provides a cost-effective, industrially feasible process for the manufacture of crystalline carvedilol form-II using novel carvedilol salts comprising a step of reacting 4-(2,3-epoxypropoxy)carbazole with 2-(2-methoxyphenoxy)ethylamine followed by acidification with mineral acid in presence of an organic solvent to yield acid addition salts, (e.g. carvedilol oxalate), treatment of the said salts with base(s) in presence of organic solvent(s), water, and isolation from the organic solvent(s) followed by crystallization from Et acetate.
REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d l9 ibib abs hitstr tot

L9 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2007:770875 HCAPLUS
DOCUMENT NUMBER: 148:545974
TITLE: A novel cost effective process for production of carvedilol phosphate
INVENTOR(S): Shankar, Sanganbhatla; Pandurang, Suryavanshi Jitendra; Sayyed, Zahid Alam
PATENT ASSIGNEE(S): Wanbury Limited, India
SOURCE: Indian Pat. Appl., 13pp.
CODEN: INXXBQ
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
IN 2007MU00929	A	20070706	IN 2007-MU929	20070517
PRIORITY APPLN. INFO.:			IN 2007-MU929	20070517

AB A novel cost effective process for the synthesis of phosphate salts of 1-(9H-carbazol-4yloxy)-3-[[2-(2-methoxyphenoxy)ethyl] amino]-propan-2-ol,(carvedilol phosphate) of formula (II) with high yields and purity is disclosed. More particularly, the invention discloses a process of preparation of crystalline phosphate salts of carvedilol using various phosphonation reagents such as phosphorous pentoxide, polyphosphoric acid, Dipotassium hydrogen phosphate, Ammonium Dihydrogen ortho phosphate, and Sodium Dihydrogen ortho phosphate in solvents selected from Acetonitrile, acetone and THF. The solvents used to prepare solvates of carvedilol dihydrogen phosphate are methanol, ethanol and iso-Pr alc.

=> d l10 ibib abs hitstr tot

L10 ANSWER 1 OF 6 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2008:832216 HCAPLUS
TITLE: Novel polymorphic forms of carvedilol dihydrogen phosphate and process for preparing the same
INVENTOR(S): Jetti, Ramakoteswara Rao; Gorantla, Asha Rani; Tyagi, Om Dutt
PATENT ASSIGNEE(S): Matrix Laboratories Limited, India
SOURCE: U.S. Pat. Appl. Publ., 30pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20080167477	A1	20080710	US 2007-852213	20070907
PRIORITY APPLN. INFO.:			IN 2007-CH46 A	20070108
			IN 2007-CH485 A	20070309

AB The present invention provides novel crystalline polymorphic forms and amorphous form of carvedilol dihydrogen phosphate characterized by different solid state techniques. The novel processes for their preparation are also disclosed.

L10 ANSWER 2 OF 6 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2007:770875 HCAPLUS
DOCUMENT NUMBER: 148:545974
TITLE: A novel cost effective process for production of carvedilol phosphate
INVENTOR(S): Shankar, Sanganbhatla; Pandurang, Suryavanshi Jitendra; Sayyed, Zahid Alam
PATENT ASSIGNEE(S): Wanbury Limited, India
SOURCE: Indian Pat. Appl., 13pp.
CODEN: INXXBQ
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
IN 2007MU00929	A	20070706	IN 2007-MU929	20070517
PRIORITY APPLN. INFO.:			IN 2007-MU929	20070517

AB A novel cost effective process for the synthesis of phosphate salts of 1-(9H-carbazol-4yloxy)-3-[[2-(2-methoxyphenoxy)ethyl] amino]-propan-2-ol,(carvedilol phosphate) of formula (II) with high yields and purity is disclosed. More particularly, the invention discloses a process of preparation of crystalline phosphate salts of carvedilol using various phosphonation reagents such as phosphorous pentoxide, polyphosphoric acid, Dipotassium hydrogen phosphate, Ammonium Dihydrogen ortho phosphate, and Sodium Dihydrogen ortho phosphate in solvents selected from Acetonitrile, acetone and THF. The solvents used to prepare solvates of carvedilol dihydrogen phosphate are methanol, ethanol and iso-Pr alc.

L10 ANSWER 3 OF 6 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2006:1338211 HCAPLUS
DOCUMENT NUMBER: 146:68735
TITLE: Crystalline forms of carvedilol and processes for their preparation
INVENTOR(S): Lifshitz, Igor; Wizel, Shlomit
PATENT ASSIGNEE(S): Teva Pharmaceutical Industries Ltd., Israel; Teva Pharmaceuticals USA, Inc.
SOURCE: PCT Int. Appl., 17pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006135757	A1	20061221	WO 2006-US22499	20060609

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

US 20070043099	A1	20070222	US 2006-450699		20060609
EP 1781611	A1	20070509	EP 2006-772705		20060609
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU					
KR 2007088507	A	20070829	KR 2007-705429		20070307
PRIORITY APPLN. INFO.:			US 2005-689776P	P	20050609
			WO 2006-US22499	W	20060609

AB This invention relates to a novel crystalline form of carvedilol, to processes for its preparation, to compns. containing it and to its use in medicine. This invention further relates to a novel process for preparing crystalline carvedilol . Thus, carvedilol 50 g and Et acetate 500 mL were put into clean flask, the slurry was heated to temperature higher than 70 °C to get full dissoln. The solution was cooled to about 0-5°C. At temperature of about 5-10° spontaneous precipitation occurred. The solid substance was filtered and washed by Et acetate.

REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 4 OF 6 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2005:216797 HCAPLUS
DOCUMENT NUMBER: 142:285152
TITLE: New crystalline forms of carvedilol
INVENTOR(S): Zupet, Rok; Grcman, Marija; Smrkolj, Matej
PATENT ASSIGNEE(S): Krka, Tovarna Zdravil D.D. Novo Mesto, Slovenia
SOURCE: PCT Int. Appl., 20 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005021504	A2	20050310	WO 2004-SI29	20040901
WO 2005021504	A3	20050602		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
SI 21616	A	20050430	SI 2003-218	20030902
EP 1660451	A2	20060531	EP 2004-775682	20040901
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				

PRIORITY APPLN. INFO.: SI 2003-218 A 20030902
WO 2004-SI29 W 20040901

AB The present invention relates to new crystalline carvedilol forms VII and IX and to processes for the preparation Particularly, this invention relates to processes of the isolation of carvedilol, using Et acetate as a solvent and preparation of an Et acetate solvate.

L10 ANSWER 5 OF 6 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2004:927171 HCAPLUS
DOCUMENT NUMBER: 141:395415
TITLE: Process for the preparation of crystalline carvedilol form-II
INVENTOR(S): Ramanjaneyulu, Gorantla Seeta; Kumar, Indukuri Venkata Sunil; Rao, Ketavarapu Narasimha; Kishore, Jammula Vera Venkata Krishna
PATENT ASSIGNEE(S): Matrix Laboratories Ltd., India
SOURCE: PCT Int. Appl., 18 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004094378	A1	20041104	WO 2004-IN104	20040416
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
IN 2003MA00328	A	20070518	IN 2003-MA328	20030421
EP 1615888	A1	20060118	EP 2004-727971	20040416
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
US 20070055069	A1	20070308	US 2005-552843	20051012
PRIORITY APPLN. INFO.:			IN 2003-MA328 A	20030421
			WO 2004-IN104 W	20040416

OTHER SOURCE(S): CASREACT 141:395415
AB The present invention provides a cost-effective, industrially feasible process for the manufacture of crystalline carvedilol form-II using novel carvedilol salts comprising a step of reacting 4-(2,3-epoxypropoxy)carbazole with 2-(2-methoxyphenoxy)ethylamine followed by acidification with mineral acid in presence of an organic solvent to yield acid addition salts, (e.g. carvedilol oxalate), treatment of the said salts with base(s) in presence of organic solvent(s), water, and isolation from the organic solvent(s) followed by crystallization from Et acetate.
REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 6 OF 6 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2003:570906 HCAPLUS
DOCUMENT NUMBER: 139:122716
TITLE: Crystalline solids of carvedilol and processes for their preparation
INVENTOR(S): Kor, Ilan; Wizel, Shlomit
PATENT ASSIGNEE(S): Teva Pharmaceutical Industries Ltd., Israel; Teva Pharmaceuticals USA, Inc.
SOURCE: PCT Int. Appl., 18 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003059807	A2	20030724	WO 2003-US1137	20030115
WO 2003059807	A3	20031204		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2472377	A1	20030724	CA 2003-2472377	20030115
AU 2003205146	A1	20030730	AU 2003-205146	20030115
US 20030166702	A1	20030904	US 2003-342905	20030115
US 6710184	B2	20040323		
EP 1474133	A2	20041110	EP 2003-703815	20030115
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
CN 1615133	A	20050511	CN 2003-802210	20030115
JP 2005515226	T	20050526	JP 2003-559922	20030115
US 20040171665	A1	20040902	US 2003-712799	20031112
ZA 2004005443	A	20050708	ZA 2004-5443	20040708
MX 2004PA06909	A	20050419	MX 2004-PA6909	20040715
NO 2004003383	A	20040813	NO 2004-3383	20040813

PRIORITY APPLN. INFO.:			
	US 2002-349310P	P	20020115
	US 2003-342905	A3	20030115
	WO 2003-US1137	W	20030115

AB This invention relates to a novel crystalline solid of carvedilol or a solvate thereof, to processes for its preparation, to compns. containing it and to its use in medicine. This invention further relates to a novel process for preparing a crystalline solid of carvedilol form II.

=> d l11 ibib abs hitstr tot

L11 ANSWER 1 OF 2 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2004:927171 HCAPLUS

DOCUMENT NUMBER: 141:395415
TITLE: Process for the preparation of crystalline carvedilol form -II
INVENTOR(S): Ramanjaneyulu, Gorantla Seeta; Kumar, Indukuri Venkata Sunil; Rao, Ketavarapu Narasimha; Kishore, Jammula Vera Venkata Krishna
PATENT ASSIGNEE(S): Matrix Laboratories Ltd., India
SOURCE: PCT Int. Appl., 18 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004094378	A1	20041104	WO 2004-IN104	20040416
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
IN 2003MA00328	A	20070518	IN 2003-MA328	20030421
EP 1615888	A1	20060118	EP 2004-727971	20040416
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
US 20070055069	A1	20070308	US 2005-552843	20051012

PRIORITY APPLN. INFO.: IN 2003-MA328 A 20030421
WO 2004-IN104 W 20040416

OTHER SOURCE(S): CASREACT 141:395415

AB The present invention provides a cost-effective, industrially feasible process for the manufacture of crystalline carvedilol form-II using novel carvedilol salts comprising a step of reacting 4-(2,3-epoxypropoxy)carbazole with 2-(2-methoxyphenoxy)ethylamine followed by acidification with mineral acid in presence of an organic solvent to yield acid addition salts, (e.g. carvedilol oxalate), treatment of the said salts with base(s) in presence of organic solvent(s), water, and isolation from the organic solvent(s) followed by crystallization from Et acetate.

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2003:570906 HCAPLUS
DOCUMENT NUMBER: 139:122716
TITLE: Crystalline solids of carvedilol and processes for their preparation
INVENTOR(S): Kor, Ilan; Wizel, Shlomit
PATENT ASSIGNEE(S): Teva Pharmaceutical Industries Ltd., Israel; Teva

Pharmaceuticals USA, Inc.
SOURCE: PCT Int. Appl., 18 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003059807	A2	20030724	WO 2003-US1137	20030115
WO 2003059807	A3	20031204		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2472377	A1	20030724	CA 2003-2472377	20030115
AU 2003205146	A1	20030730	AU 2003-205146	20030115
US 20030166702	A1	20030904	US 2003-342905	20030115
US 6710184	B2	20040323		
EP 1474133	A2	20041110	EP 2003-703815	20030115
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
CN 1615133	A	20050511	CN 2003-802210	20030115
JP 2005515226	T	20050526	JP 2003-559922	20030115
US 20040171665	A1	20040902	US 2003-712799	20031112
ZA 2004005443	A	20050708	ZA 2004-5443	20040708
MX 2004PA06909	A	20050419	MX 2004-PA6909	20040715
NO 2004003383	A	20040813	NO 2004-3383	20040813

PRIORITY APPLN. INFO.:			
US 2002-349310P	P	20020115	
US 2003-342905	A3	20030115	
WO 2003-US1137	W	20030115	

AB This invention relates to a novel crystalline solid of carvedilol or a solvate thereof, to processes for its preparation, to compns. containing it and to its use in medicine. This invention further relates to a novel process for preparing a crystalline solid of carvedilol form II.

=> d l12 ibib abs hitstr tot

L12 ANSWER 1 OF 6 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2003:570906 HCAPLUS
DOCUMENT NUMBER: 139:122716
TITLE: Crystalline solids of carvedilol and processes for their preparation
INVENTOR(S): Kor, Ilan; Wizel, Shlomit
PATENT ASSIGNEE(S): Teva Pharmaceutical Industries Ltd., Israel; Teva Pharmaceuticals USA, Inc.
SOURCE: PCT Int. Appl., 18 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003059807	A2	20030724	WO 2003-US1137	20030115 <--
WO 2003059807	A3	20031204		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2472377	A1	20030724	CA 2003-2472377	20030115 <--
AU 2003205146	A1	20030730	AU 2003-205146	20030115 <--
US 20030166702	A1	20030904	US 2003-342905	20030115 <--
US 6710184	B2	20040323		
EP 1474133	A2	20041110	EP 2003-703815	20030115
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
CN 1615133	A	20050511	CN 2003-802210	20030115
JP 2005515226	T	20050526	JP 2003-559922	20030115
US 20040171665	A1	20040902	US 2003-712799	20031112
ZA 2004005443	A	20050708	ZA 2004-5443	20040708
MX 2004PA06909	A	20050419	MX 2004-PA6909	20040715
NO 2004003383	A	20040813	NO 2004-3383	20040813

PRIORITY APPLN. INFO.:
US 2002-349310P P 20020115
US 2003-342905 A3 20030115
WO 2003-US1137 W 20030115

AB This invention relates to a novel crystalline solid of carvedilol or a solvate thereof, to processes for its preparation, to compns. containing it and to its use in medicine. This invention further relates to a novel process for preparing a crystalline solid of carvedilol form II.

L12 ANSWER 2 OF 6 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2003:282536 HCAPLUS
DOCUMENT NUMBER: 138:292802
TITLE: Pseudopolymorphic forms of carvedilol
INVENTOR(S): Bubendorf, Andre Gerard; Gabel, Rolf-dieter; Henning, Michael; Krimmer, Siegfried; Neugebauer, Guenter; Preis, Walter; Wirl, Alexander
PATENT ASSIGNEE(S): F. Hoffmann-La Roche Ag, Switz.
SOURCE: PCT Int. Appl., 35 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

WO 2003029214	A1	20030410	WO 2002-EP10451	20020918 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2460486	A1	20030410	CA 2002-2460486	20020918 <--
AU 2002338726	B9	20030414	AU 2002-338726	20020918 <--
AU 2002338726	A1	20030414		
AU 2002338726	B2	20070315		
EP 1432681	A1	20040630	EP 2002-777139	20020918
EP 1432681	B1	20070808		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
BR 2002012927	A	20041013	BR 2002-12927	20020918
CN 1558900	A	20041229	CN 2002-818741	20020918
JP 2005507899	T	20050324	JP 2003-532464	20020918
AT 369339	T	20070815	AT 2002-777139	20020918
RU 2308449	C2	20071020	RU 2004-113209	20020918
ES 2291503	T3	20080301	ES 2002-777139	20020918
US 20030119893	A1	20030626	US 2002-255290	20020926 <--
MX 2004PA02826	A	20040702	MX 2004-PA2826	20040325
KR 752549	B1	20070830	KR 2004-704578	20040327
US 20040198812	A1	20041007	US 2004-827859	20040420
US 20060148878	A1	20060706	US 2006-325754	20060105

PRIORITY APPLN. INFO.:	EP 2001-123422	A	20010928
	WO 2002-EP10451	W	20020918
	US 2002-255290	B1	20020926
	US 2004-827859	B1	20040420

AB The present invention is related to pseudopolymorphic forms of 1-(4-carbazolyloxy)-3[2-(2-methoxyphenoxy)ethylamino]-2-propanol (carvedilol) or its optically active forms or pharmaceutically acceptable salts, processes for their preparation, and pharmaceutical compns. containing them for the treatment or prophylaxis of cardiac diseases.

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 3 OF 6 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER:	2002:556143 HCAPLUS
DOCUMENT NUMBER:	137:125080
TITLE:	Process for preparing heterocyclic indene analogs by cyclocarbonylation at moderate temperatures and catalyst loading
INVENTOR(S):	Scalone, Michelangelo; Zeibig, Thomas Albert
PATENT ASSIGNEE(S):	Hoffmann-LaRoche Inc., Switz.
SOURCE:	U.S. Pat. Appl. Publ., 19 pp. CODEN: USXXCO
DOCUMENT TYPE:	Patent
LANGUAGE:	English
FAMILY ACC. NUM. COUNT:	1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20020099223	A1	20020725	US 2002-54462	20020122 <--
US 6777559	B2	20040817		
CA 2434408	A1	20020801	CA 2002-2434408	20020122 <--
WO 2002059089	A2	20020801	WO 2002-EP583	20020122 <--
WO 2002059089	A3	20021031		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002247645	A1	20020806	AU 2002-247645	20020122 <--
EP 1355880	A2	20031029	EP 2002-716673	20020122 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004519465	T	20040702	JP 2002-559391	20020122
JP 4056883	B2	20080305		
IN 2003CN01126	A	20050422	IN 2003-CN1126	20030722
MX 2003PA06606	A	20030922	MX 2003-PA6606	20030723 <--
US 20040127723	A1	20040701	US 2004-763296	20040122
US 7169935	B2	20070130		
PRIORITY APPLN. INFO.:			EP 2001-101584	A 20010125
			US 2002-54462	A3 20020122
			WO 2002-EP583	W 20020122

OTHER SOURCE(S): CASREACT 137:125080; MARPAT 137:125080

AB A process for the preparation heterocyclic indene analogs, especially with the preparation of 4-hydroxycarbazole or N-protected 4-hydroxycarbazole, involves cyclocarbonylation followed by saponification This process avoids high temps. and high catalyst loadings.

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 4 OF 6 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2000:383901 HCAPLUS

DOCUMENT NUMBER: 133:22442

TITLE: Pharmaceutical combination preparations for treatment of cardiac and cardiovascular disorders

INVENTOR(S): Heller, Rudolf

PATENT ASSIGNEE(S): F. Hoffmann-La Roche A.-G., Switz.

SOURCE: PCT Int. Appl., 17 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000032174	A2	20000608	WO 1999-EP8972	19991120 <--

WO 2000032174 A3 20001116
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

CA 2352361	A1	20000608	CA 1999-2352361	19991120	<--
CA 2352361	C	20070102			
BR 9915610	A	20010814	BR 1999-15610	19991120	<--
EP 1131072	A2	20010912	EP 1999-957320	19991120	<--
EP 1131072	B1	20030423			
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO					
TR 200101470	T2	20011121	TR 2001-1470	19991120	<--
TR 200200981	T2	20020621	TR 2002-981	19991120	<--
TR 200200982	T2	20020621	TR 2002-982	19991120	<--
JP 2002531395	T	20020924	JP 2000-584870	19991120	<--
AT 238056	T	20030515	AT 1999-957320	19991120	<--
PT 1131072	T	20030829	PT 1999-957320	19991120	<--
AU 765977	B2	20031009	AU 2000-15065	19991120	<--
ES 2195638	T3	20031201	ES 1999-957320	19991120	<--
US 6403579	B1	20020611	US 1999-447872	19991123	<--
TW 228414	B	20050301	TW 2000-89103144	20000223	
ZA 2001004280	A	20020826	ZA 2001-4280	20010524	<--
MX 2001PA05300	A	20010910	MX 2001-PA5300	20010525	<--
US 20020052367	A1	20020502	US 2001-946205	20010905	<--
US 20040087578	A1	20040506	US 2003-693243	20031024	
JP 2007077160	A	20070329	JP 2006-284476	20061019	

PRIORITY APPLN. INFO.:

EP 1998-122489	A	19981127
JP 2000-584870	A3	19991120
WO 1999-EP8972	W	19991120
US 1999-447872	A3	19991123
US 2001-946205	B1	20010905

AB Pharmaceutical prepns. for the treatment of cardiac and cardiovascular disorders such as hypertension, angina pectoris, cardiac insufficiency, and illnesses associated therewith contain carvedilol, a β-blocker with addnl. α1-blocking activity, or a salt thereof and hydrochlorothiazide, a diuretic, or a salt thereof as a fixed combination of active substances, as well as usual additives. The process for production of the combination preparation permits the 2 active substance granulates to be pressed to a stable tablet in 1 operation, as follows: granulates of the 2 agents, each having a moisture content of 6-20% and a bulk d. of 0.1-1.5 g/mL, and the granulate moisture content and bulk d. of the 2 granulates differing from one another by ≤30%. are combined to a press mass which is compressed to a solid dosage form, preferably a tablet. Since carvedilol is light sensitive, the dosage form is coated with a light-protecting film. At disintegrant contents >5%, the coating is applied at an initial spray rate sufficiently low to permit formation of a film on the tablet surface under conditions of air supply and temperature which remove the water of the film suspension as rapidly as possible from the tablet surface; after this critical phase of film formation is complete, the spray rate is increased to that conventional for film-coating. Thus, tablets were prepared containing carvedilol 25.000, hydrochlorothiazide 12.500, sucrose 25.000, lactose-H2O 28.060,

PVP 1.780, crosslinked PVP 20.170, microcryst. cellulose 10.000, highly dispersed SiO2 5.320, and Mg stearate 2.170 mg, and coated with a mixture of Et acrylate/Me acrylate copolymer 2.248, Na citrate 0.308, hydroxypropylmethylcellulose 1.018, Macrogol 0.644, talc 1.624, TiO2 0.950, indigo carmine color lacquer 0.170, polysorbate 80 0.034, and dimethicone 0.004 mg.

L12 ANSWER 5 OF 6 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1999:96212 HCAPLUS
DOCUMENT NUMBER: 130:158418
TITLE: Thermodynamically stable modification of 1-(4-carbazolyloxy)-3-[2-(2-methoxyphenoxy)ethylamino]-2-propanol, process for its preparation and pharmaceutical compositions containing it
INVENTOR(S): Reinholz, Erhard; Beyer, Peter
PATENT ASSIGNEE(S): Boehringer Mannheim G.m.b.H., Germany
SOURCE: PCT Int. Appl., 20 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9905105	A1	19990204	WO 1998-EP4475	19980718 <--
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 893440	A1	19990127	EP 1997-112491	19970722 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
CA 2296637	A1	19990204	CA 1998-2296637	19980718 <--
CA 2296637	C	20051115		
AU 9886319	A	19990216	AU 1998-86319	19980718 <--
AU 740453	B2	20011101		
EP 1000027	A1	20000517	EP 1998-937576	19980718 <--
EP 1000027	B1	20030402		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
BR 9810776	A	20000919	BR 1998-10776	19980718 <--
HU 2000003198	A2	20010328	HU 2000-3198	19980718 <--
HU 2000003198	A3	20021028		
JP 2001510824	T	20010807	JP 2000-504104	19980718 <--
NZ 502136	A	20020531	NZ 1998-502136	19980718 <--
AT 236123	T	20030415	AT 1998-937576	19980718 <--
RU 2202542	C2	20030420	RU 2000-103033	19980718 <--
IL 133677	A	20040601	IL 1998-133677	19980718
PL 191602	B1	20060630	PL 1998-338432	19980718
MX 200000507	A	20001109	MX 2000-507	20000113 <--
NO 2000000301	A	20000121	NO 2000-301	20000121 <--

NO 313588	B1	20021028		
HK 1029339	A1	20040213	HK 2001-100012	20010102
US 20030036559	A1	20030220	US 2002-166188	20020610 <--
US 6730326	B2	20040504		
PRIORITY APPLN. INFO.:			EP 1997-112491	A 19970722
			WO 1998-EP4475	W 19980718
			US 2000-463346	B1 20000121

AB The present invention relates to a new thermodynamically stable modification of Carvedilol, pharmacol. acceptable salts, or optically active forms thereof, processes for the prepn., and pharmaceutical compns. containing it. Crude carvedilol is heated with MeOH and CXA-coal to give forms I and II and these are recrystd. in isopropanol to give pure form I.

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 6 OF 6 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1999:90419 HCAPLUS
DOCUMENT NUMBER: 130:144175
TITLE: Thermodynamically stable modification of carvedilol, process for its preparation and pharmaceutical compositions containing it
INVENTOR(S): Beyer, Peter; Reinholz, Erhard
PATENT ASSIGNEE(S): Boehringer Mannheim GmbH, Germany
SOURCE: Eur. Pat. Appl., 11 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 893440	A1	19990127	EP 1997-112491	19970722 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
IN 1998MA01596	A	20050304	IN 1998-MA1596	19980717
CA 2296637	A1	19990204	CA 1998-2296637	19980718 <--
CA 2296637	C	20051115		
WO 9905105	A1	19990204	WO 1998-EP4475	19980718 <--
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 9886319	A	19990216	AU 1998-86319	19980718 <--
AU 740453	B2	20011101		
EP 1000027	A1	20000517	EP 1998-937576	19980718 <--
EP 1000027	B1	20030402		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
TR 200000148	T2	20000721	TR 2000-148	19980718 <--
BR 9810776	A	20000919	BR 1998-10776	19980718 <--

HU 2000003198	A2	20010328	HU 2000-3198	19980718	<--
HU 2000003198	A3	20021028			
JP 2001510824	T	20010807	JP 2000-504104	19980718	<--
NZ 502136	A	20020531	NZ 1998-502136	19980718	<--
TW 505631	B	20021011	TW 1998-87111738	19980718	<--
AT 236123	T	20030415	AT 1998-937576	19980718	<--
RU 2202542	C2	20030420	RU 2000-103033	19980718	<--
PT 1000027	T	20030731	PT 1998-937576	19980718	<--
CN 1125047	B	20031022	CN 1998-807436	19980718	<--
ES 2195366	T3	20031201	ES 1998-937576	19980718	<--
IL 133677	A	20040601	IL 1998-133677	19980718	
PL 191602	B1	20060630	PL 1998-338432	19980718	
CZ 296947	B6	20060816	CZ 2000-221	19980718	
ZA 9806475	A	20000121	ZA 1998-6475	19980721	<--
MX 200000507	A	20001109	MX 2000-507	20000113	<--
NO 2000000301	A	20000121	NO 2000-301	20000121	<--
NO 313588	B1	20021028			
HK 1029339	A1	20040213	HK 2001-100012	20010102	
US 20030036559	A1	20030220	US 2002-166188	20020610	<--
US 6730326	B2	20040504			

PRIORITY APPLN. INFO.: EP 1997-112491 A 19970722
WO 1998-EP4475 W 19980718
US 2000-463346 B1 20000121

AB A new thermodynamically stable modification of 1-(4-carbazolyloxy)-3-[2-(2-methoxyphenoxy)ethylamino]-2-propanol (carvedilol), pharmacol. acceptable salts, or optically active forms thereof, processes for the preparation, and pharmaceutical compns. containing it is disclosed. Thus, 300 g crude carvedilol, 15 g CXA-coal and 2800 methanol was heated for 15 min under reflux, then the hot solution was filtered, washed with 300 mL hot methanol and heated under reflux again. Subsequently the solution was cooled down to 0° and the product was isolated, washed with methanol and dried to obtain 203-255 g of pure form I. Form II can be obtained by addnl. recrystn. process in isopropanol.

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> log y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	155.21	155.42
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-26.40	-26.40

STN INTERNATIONAL LOGOFF AT 08:53:24 ON 16 JUL 2008